The present invention is directed to compounds of formula (I),
and pharmaceutically acceptable salts and solvates thereof, their synthesis, and their use as modulators or inhibitors of the human immunodeficiency virus (“HIV”) integrase enzyme.
Design and Synthesis of Novel <i>N</i>-Hydroxy-Dihydronaphthyridinones as Potent and Orally Bioavailable HIV-1 Integrase Inhibitors
作者:Ted W. Johnson、Steven P. Tanis、Scott L. Butler、Deepak Dalvie、Dorothy M. DeLisle、Klaus R. Dress、Erik J. Flahive、Qiyue Hu、Jon E. Kuehler、Atsuo Kuki、Wen Liu、Guy A. McClellan、Qinghai Peng、Michael B. Plewe、Paul F. Richardson、Graham L. Smith、Jim Solowiej、Khanh T. Tran、Hai Wang、Xiaoming Yu、Junhu Zhang、Huichun Zhu
DOI:10.1021/jm200208d
日期:2011.5.12
HIV-1 integrase (IN) is one of three enzymes encoded by the HIV genome and is essential for viral replication, and HIV-1 IN inhibitors have emerged as a new promising class of therapeutics. Recently, we reported the synthesis of orally bioavailable azaindole hydroxamic acids that were potent inhibitors of the HIV-1 IN enzyme. Here we disclose the design and synthesis of novel tricyclic N-hydroxy-dihydronaphthyridinones as potent, orally bioavailable HIV-1 integrase inhibitors displaying excellent ligand and lipophilic efficiencies.
Catalytic asymmetric aza-Michael addition of fumaric monoacids with multifunctional thiourea/boronic acids
synthesis of N-hydroxyaspartic acid derivatives using chiral multifunctional thiourea/boronic acid organocatalysts was developed. A series of fumaric monoacids underwent an intermolecular asymmetric aza-Michael addition of O-alkyl hydroxylamines in excellent regioselectivity. The addition of another carboxylic acid raised the enantiomeric enrichment up to 97% ee. O-Deprotection of the aza-Michael adduct